Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Agios Pharmaceuticals, Inc.”

93 pharma patents match "Agios Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 93
Index total 30,257
Page 1 / 4

Quick answer

This filtered view shows 93 pharmaceutical patents matching "Agios Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

93 results for “Agios Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12428376

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted

  2. US 12377093

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted

  3. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted

  4. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted

  5. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Agios Pharmaceuticals, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted

  6. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Agios Pharmaceuticals, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted

  7. US 11872225

    Pyruvate kinase modulators and use thereof

    Agios Pharmaceuticals, Inc. · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted

  8. US 11866411

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted

  9. US 11793806

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted

  10. US 11590132

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  11. US 11464775

    Pyruvate kinase modulators and use thereof

    Agios Pharmaceuticals, Inc. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  12. US 11458127

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  13. US 11364240

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted

  14. US 11254652

    Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

    Agios Pharmaceuticals, Inc. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  15. US 11234976

    Methods of using pyruvate kinase activators

    Agios Pharmaceuticals, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  16. US 11040036

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted

  17. US 11021515

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted

  18. US 10988448

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted

  19. US 10980788

    Therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  20. US 10946023

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  21. US 10905692

    Combination therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Feb 2, 2021 · Expires Jan 28, 2041

    granted

  22. US 10800782

    Inhibitors of cellular metabolic processes

    Agios Pharmaceuticals, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  23. US 10799490

    Pharmaceutical compositions of therapeutically active compounds

    Agios Pharmaceuticals, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  24. US 10780093

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.